沃森生物(300142.SZ)與艾博生物就共同開發帶狀皰疹mRNA疫苗達成合作協議
格隆匯5月12日丨沃森生物(300142.SZ)公佈,2020年5月11日,公司第四屆董事會第九次會議審議通過了《關於與蘇州艾博生物科技有限公司共同促進基於mRNA的帶狀皰疹疫苗產品研發及商業化並簽署<技術開發合作協議>的議案》,董事會同意公司與蘇州艾博生物科技有限公司(“艾博生物”)簽署《技術開發合作協議》。本着優勢互補、合作共贏的原則,沃森生物與艾博生物就共同開發帶狀皰疹mRNA疫苗達成合作協議,致力於共同合作開展帶狀皰疹mRNA疫苗的臨牀前研究、臨牀研究並實施商業化生產。
此次合作的主要目的為基於艾博生物在mRNA疫苗分子設計、mRNA化學修飾以及核酸藥物靶向遞送製劑方面擁有國內領先的核心技術;基於沃森生物在疫苗註冊、臨牀研究、產業化和市場營銷方面擁有豐富的經驗和核心能力。本着優勢互補、合作共贏的原則,雙方就共同開發帶狀皰疹mRNA疫苗達成合作協議,致力於共同合作開展帶狀皰疹mRNA疫苗的臨牀前研究、臨牀研究並實施商業化生產。
公司與艾博生物共同促進基於mRNA的帶狀皰疹疫苗產品研發及商業化有利於公司建立mRNA疫苗技術平台,有利於公司新疫苗品種的研發,是綜合考慮了公司整體經營發展規劃和經營現狀而做出的謹慎決策,符合公司的整體發展戰略。本次技術開發合作不會對公司近期財務狀況和經營狀況產生重大影響,不存在損害上市公司及股東利益的情形。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.